Evommune filed to go public to finance late‑stage development of two mid‑stage candidates targeting chronic inflammatory conditions: EVO756, an oral MRGPRX2 antagonist for chronic spontaneous urticaria and atopic dermatitis, and EVO301, an IL‑18 neutralizing fusion protein. The company said proceeds will support Phase‑2 studies and planned Phase‑2/3 expansion for EVO756, with top‑line Phase‑2 results expected in 2026 for select programs. Evommune’s IPO filing and investor materials emphasize oral delivery for mast cell modulation and differentiated biology versus existing biologics. The move joins a small cluster of biotechs returning to public markets in 2025, reflecting improving IPO windows for clinical‑stage specialty immunology developers. Investors will watch upcoming readouts and the company’s cash runway as key valuation drivers.